LitAlert ~~ GeneLit.com

    • Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    • ElBiad O, Laraqui A, El Boukhrissi F, Mounjid C, Lamsisi M, Bajjou T, Elannaz H, Lahlou AI, Kouach J, Benchekroune K, Oukabli M, Chahdi H, Ennaji MM, Tanz R, Sbitti Y, Ichou M, Ennibi K, Badaoui B, Sekhsokh Y.
    • BMC Cancer. 2022 Feb 25;22(1):208. doi: 10.1186/s12885-022-09181-4.
    • A Swedish Genome-Wide Haplotype Association Analysis Identifies a Novel Breast Cancer Susceptibility Locus in 8p21.2 and Characterizes Three Loci on Chromosomes 10, 11 and 16.
    • Barnekow E, Liu W, Helgadottir HT, Michailidou K, Dennis J, Bryant P, Thutkawkorapin J, Wendt C, Czene K, Hall P, Margolin S, Lindblom A.
    • Cancers (Basel). 2022 Feb 25;14(5):1206. doi: 10.3390/cancers14051206.
    • CHEK2p.I157T Mutation Is Associated with Increased Risk of Adult-Type Ovarian Granulosa Cell Tumors.
    • Švajdler P, Vasovcák P, Švajdler M, Šedivcová M, Urbán V, Michal M, Mezencev R.
    • Cancers (Basel). 2022 Feb 25;14(5):1208. doi: 10.3390/cancers14051208.
    • Association between germline pathogenic variants and breast cancer risk in Japanese women: the HERPACC study.
    • Kasugai Y, Kohmoto T, Taniyama Y, Koyanagi YN, Usui Y, Iwase M, Oze I, Yamaguchi R, Ito H, Imoto I, Matsuo K.
    • Cancer Sci. 2022 Feb 25. doi: 10.1111/cas.15312. Epub ahead of print.
    • Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants.
    • Saule C, Menu-Hespel S, Carton M, Malhaire C, Cherel P, Reyal F, Le Mentec M, Guillot E, Donnadieu A, Callet N, Frank S, Coussy F, Stoppa-Lyonnet D, Mouret-Fourme E.
    • Eur J Hum Genet. 2022 Feb 25. doi: 10.1038/s41431-022-01049-2. Epub ahead of print.
    • An update on the safety of olaparib for treating ovarian cancer.
    • Cottrell K, Clark CL, Penson RT.
    • Expert Opin Drug Saf. 2022 Feb 25. doi: 10.1080/14740338.2022.2047176. Epub ahead of print.
    • Review
    • Rates of Variants of Uncertain Significance (VUS) among Patients with Breast Cancer Undergoing Genetic Testing; Regional Perspectives.
    • Abdel-Razeq H, Tamimi F, Abujamous L, Abdel-Razeq R, Abunasser M, Edaily S, Abdulelah H, Abu-Khashabeh R, Bater R.
    • Front Oncol. 2022 Feb 25;10:673094. doi: 10.3389/fonc.2022.673094.
    • Pancreatic cancer risk to siblings of probands in bilineal cancer settings.
    • Rabe KG, Stevens MA, Toledo Hernández A, Chandra S, Hubbard JM, Kemppainen JL, Majumder S, Petersen GM.
    • Genet Med. 2022 Feb 25. doi: 10.1016/j.gim.2022.01.016. Epub ahead of print.
    • MRI appearance of BRCA-associated prostate cancer.
    • Kamal O, Foster BR, Young DJ, Hansel DE, Coakley FV.
    • Clin Imaging. 2022 Feb 19;84:135-139. doi: 10.1016/j.clinimag.2022.02.007. Epub ahead of print.
    • Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
    • Wang Y, Song Z, Zhang S, Wang X, Li P.
    • Eur J Surg Oncol. 2022 Feb 18:S0748-7983(22)00113-5. doi: 10.1016/j.ejso.2022.02.019. Epub ahead of print.
    • Meta-Analysis